Noji Takehiro, Hirano Satoshi, Tanaka Kimitaka, Matsui Aya, Nakanishi Yoshitsugu, Asano Toshimichi, Nakamura Toru, Tsuchikawa Takahiro
Department of Gastroenterological Surgery II, Faculty of Medicine, Hokkaido University, Sapporo City 060-8638, Japan.
Cancers (Basel). 2022 May 27;14(11):2672. doi: 10.3390/cancers14112672.
Perihilar cholangiocarcinoma (PHCC) is one of the most intractable gastrointestinal malignancies. These tumours lie in the core section of the biliary tract. Patients who undergo curative surgery have a 40-50-month median survival time, and a five-year overall survival rate of 35-45%. Therefore, curative intent surgery can lead to long-term survival. PHCC sometimes invades the surrounding tissues, such as the portal vein, hepatic artery, perineural tissues around the hepatic artery, and hepatic parenchyma. Contralateral hepatic artery invasion is classed as T4, which is considered unresectable due to its "locally advanced" nature. Recently, several reports have been published on concomitant hepatic artery resection (HAR) for PHCC. The morbidity and mortality rates in these reports were similar to those non-HAR cases. The five-year survival rate after HAR was 16-38.5%. Alternative procedures for arterial portal shunting and non-vascular reconstruction (HAR) have also been reported. In this paper, we review HAR for PHCC, focusing on its history, diagnosis, procedures, and alternatives. HAR, undertaken by established biliary surgeons in selected patients with PHCC, can be feasible.
肝门部胆管癌(PHCC)是最难治疗的胃肠道恶性肿瘤之一。这些肿瘤位于胆道的核心部位。接受根治性手术的患者中位生存时间为40 - 50个月,五年总生存率为35% - 45%。因此,根治性手术可实现长期生存。PHCC有时会侵犯周围组织,如门静脉、肝动脉、肝动脉周围的神经组织和肝实质。对侧肝动脉侵犯被归类为T4期,因其“局部进展”的性质而被认为无法切除。最近,有几篇关于肝门部胆管癌同期肝动脉切除(HAR)的报道发表。这些报道中的发病率和死亡率与非肝动脉切除病例相似。肝动脉切除术后的五年生存率为16% - 38.5%。也有关于动脉门静脉分流和非血管重建(肝动脉切除)替代手术的报道。在本文中,我们回顾肝门部胆管癌的肝动脉切除,重点关注其历史、诊断、手术方法及替代方案。由经验丰富的胆道外科医生对选定的肝门部胆管癌患者进行肝动脉切除是可行的。